irinotecan has been researched along with Dermatitis Medicamentosa in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Boeck, S; Caca, K; Ettrich, TJ; Fischer von Weikersthal, L; Freiberg-Richter, J; Fuchs, M; Haas, M; Heinemann, V; Held, S; Kanzler, S; Kruger, S; Kullmann, F; Kunzmann, V; Lerch, MM; Reinacher-Schick, A; Schenk, M; Siveke, JT; Westphalen, CB | 1 |
| Alonso, B; Aranda, E; Arrivi, A; Bando, I; Carrato, A; Conde, V; Díaz-Rubio, E; Elez, E; Gallego, J; Grávalos, C; López, C; Ortiz, MJ; Pericay, C; Ruiz de Mena, I; Safont, MJ; Tabernero, J; Valladares-Ayerbes, M | 1 |
| Albares, MP; del Carmen Leiva-Salinas, M; Frances, L; Guijarro, J; Ramon, R | 1 |
| Kaniwa, N | 1 |
| Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM | 1 |
| Flint, S; Galvin, S; Nestor, LA | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Eng, C | 1 |
| Alonso, V; Antón, I; Arrivi, A; Cirera, L; Constenla, M; Escudero, P; García, P; Grande, C; Guasch, I; López, LJ; Losa, F; Martin, C; Méndez, M; Moreno, I; Pericay, C; Quintero-Aldana, G; Roca, JM; Salud, A; Vicente, P; Yubero, A | 1 |
| Caron, J; Chalbos, P; Dereure, O; Duffour, J; Fiess, C; Garcin, A; Gestin-Boyer, C; Guillot, B; Portales, F; Samalin, E; Thézenas, S; Ychou, M | 1 |
| Cats, A; Ciardiello, F; Gallerani, E; Gelderblom, H; Glimelius, B; Hendlisz, A; Humblet, Y; Moehler, M; Peeters, M; Sagaert, X; Schlichting, M; Tejpar, S; Van Cutsem, E; Vanbeckevoort, D; Vermorken, JB; Viret, F; Vlassak, S | 1 |
| Needle, MN | 1 |
| Braun-Falco, M; Holtmann, C; Lordick, F; Ring, J | 1 |
| Takiuchi, H | 1 |
| Bearzi, I; Berardi, R; Biscotti, T; Cascinu, S; Catalano, V; Falcone, A; Labianca, R; Loupakis, F; Mandolesi, A; Pierantoni, C; Quadri, A; Scartozzi, M; Zaniboni, A; Zorzi, F | 1 |
| Laurent-Puig, P; Lièvre, A | 1 |
5 review(s) available for irinotecan and Dermatitis Medicamentosa
| Article | Year |
|---|---|
[Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs].
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Deoxycytidine; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Genomics; Glucuronosyltransferase; HLA Antigens; Humans; International Cooperation; Irinotecan; Japan; Pharmacogenetics; Precision Medicine; Prodrugs; Product Surveillance, Postmarketing | 2015 |
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Eruptions; Evidence-Based Medicine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Risk Factors | 2009 |
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
[Cetuximab].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Approval; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Mice | 2007 |
[Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclin D1; Drug Eruptions; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gene Dosage; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Mutation; Neoplasm Proteins; Panitumumab; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Vascular Endothelial Growth Factor A | 2008 |
6 trial(s) available for irinotecan and Dermatitis Medicamentosa
| Article | Year |
|---|---|
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Young Adult | 2018 |
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Colorectal Neoplasms; Diarrhea; Drug Eruptions; Epiregulin; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Magnesium; Male; Membrane Proteins; Middle Aged; Panitumumab; Peritoneal Neoplasms; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Salvage Therapy; Survival Rate; Treatment Outcome; Water-Electrolyte Imbalance | 2019 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2010 |
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Irinotecan; Male; Middle Aged | 2012 |
6 other study(ies) available for irinotecan and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Localized skin necrosis by bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Drug Eruptions; Humans; Irinotecan; Male; Middle Aged; Necrosis; Skin | 2013 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male | 2017 |
Unusual case of hyperpigmentation secondary to irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Female; Humans; Hyperpigmentation; Irinotecan; Middle Aged; Mouth Mucosa; Nails; Neoplasm Recurrence, Local | 2016 |
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Competence; Colorectal Neoplasms; Dermatology; Drug Eruptions; Humans; Irinotecan; Medical Oncology; Middle Aged; Neoplasm Metastasis; Observer Variation; Pilot Projects | 2010 |
[Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma].
Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Folliculitis; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Skin | 2006 |
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Eruptions; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; NF-kappa B; Survival Rate | 2007 |